Fairvalue-Calculator Fairvalue-Calculator
EN DE

PT. Penta Valent Tbk (PEVE) Fair Value & Analysis

Healthcare · ID · Market cap 494B IDR

Price310.00 IDR
Fair Value654.86 IDR
Upside+111.2%
Quality91/100
Evidence: High Range 460.65 IDR – 822.56 IDR

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

PT. Penta Valent Tbk (PEVE) currently trades at 310.00 IDR, while our model-based Fair Value estimate is 654.86 IDR — implying the stock looks roughly 111.2% undervalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

PT. Penta Valent Tbk engages in the distributions of pharmaceutical products, medical equipment, and consumer products in Indonesia. The company was founded in 1968 and is headquartered in Kebon Jeruk, Indonesia.

Open the full interactive analysis →

Similar stocks

JD Health International Inc (JDHIF) +404% Alibaba Health Information Technology Limited (ALBBY) -20% Raia Drogasil S.A (RADL3) -8% Yifeng Pharmacy Chain Co (603939) +5% Clicks Group (CLCGY) +45% Sugi Holdings (SGIPF) +295%

Frequently asked questions

Is PT. Penta Valent Tbk (PEVE) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 654.86 IDR versus a price of 310.00 IDR — about +111% (undervalued). Model-based estimate, not financial advice.
What is the fair value of PEVE?
Our 21-model fair value for PT. Penta Valent Tbk is 654.86 IDR (as of Jun 25, 2026), built from audited fundamentals. The current price is 310.00 IDR.
What is the quality score of PEVE?
PT. Penta Valent Tbk has a Quality Score of 91/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.